Aegis Starts SGYP, IRWD, AMRN, MDVN at Buy, PLX at Hold

Article Stock Quotes (5) Comments (0)

Aegis Capital's Raghuram Selvaraju initiated coverage on a number of Biotech stocks Tuesday morning:

• Synergy Pharma (Nasdaq: SGYP) with a Buy rating and a $25 price target.
  
• Ironwood Pharma (Nasdaq: IRWD) with a Buy rating and a $17 price target.
  
• Amarin (Nasdaq: AMRN) with a Buy rating and a $25 price target.
  
• Medivation (Nasdaq: MDVN) with a Buy rating and a $120 price target.
  
• Protalix (NYSE: PLX) with a Hold rating

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
• Goldman Sachs Resumes Coverage on Aetna (AET) at Buy
• Wells Fargo Starts Taylor Morrison Home (TMHC) at Outperform

Create E-mail Alert Related Categories

New Coverage

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?